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Background. L-carnitine has protective effects against various types of injury. This study
was designed to evaluate the beneﬁcial effects of L-carnitine on pancreatic and renal
injuries caused by cyclosporine (CsA).
Methods. Rats maintained on a low sodium diet were given vehicle (olive oil, 1 mL/kg/d),
CsA (15 mg/kg/d), L-carnitine (50 or 200 mg/kg/d), or a combination of CsA and
L-carnitine for 4 weeks. The impact of L-carnitine on pancreatic injury was assessed by
blood glucose levels, plasma insulin concentrations, and hemoglobulin A1c (HbA1c).
In addition, the protective effects of L-carnitine against CsA-induced kidney injury were
evaluated in terms of renal function, histopathology (inﬂammatory cell inﬂux and
tubulointerstitial ﬁbrosis), oxidative stress (8-hydroxy 20-deoxyguanosine, 8-OHdG),
transforming growth factor-betal (TGF-b1), apoptosis (caspase-3), and autophagy
(LC3-II).
Results. CsA treatment caused diabetes, renal dysfunction, tubulointerstitial inﬂam-
mation (ED-1-positive cells), and ﬁbrosis, which were accompanied by an increase in
8-OHdG production and upregulation of TGF-b1, caspase-3, and LC3-II. Concomitant
administration of L-carnitine increased plasma insulin concentrations, decreasing
plasma glucose and HbA1c levels. In the kidney, L-carnitine induced dose-dependent
improvement of renal function, inﬂammation, and ﬁbrosis in parallel with suppression
of the expression of TGF-b1 and 8-OHdG. Furthermore, the administration of
L-carnitine at a high dose inhibited the expression of caspase-3 and LC3-II.
Conclusion. These ﬁndings suggest that L-carnitine has a protective effect against
CsA-induced pancreatic and renal injuries.DESPITE THE DEVELOPMENT of newer immuno-suppressants, cyclosporine (CsA) remains a potent
immunosuppressive agent that is used for treating multi-
organ transplantation and autoimmune diseases. However,
the clinical usage of CsA is frequently impeded by itsNephrology & Dialysis Unit, Department of Internal
.X., S.G.P., J.J., M.R.F., D.M.L., C.L.), YanBian
ospital, YanJi, JiLin, PR China; Convergent Research
in Immunologic Disease (S.G.P., C.W.Y.), The Catholic
f Korea, Seoul, Korea; Transplant Research Center
.Y.), Seoul StMary’sHospital, College ofMedicine, The
versity of Korea, Seoul, Korea; Division of Nephrology
First Hospital of JiLin University, ChangChun, JiLin,
and Division of Nephrology (B.H.G.), ZhongShan
aLian University, DaLian, LiaoNing, PR China.
right ª 2013 Published by Elsevier Inc.
enue South, New York, NY 10010-1710
ion Proceedings, 45, 3127e3134 (2013)
der CC BY-NC-ND license.nephrotoxic effects in terms of acute and chronic nephro-
toxicity. Acute CsA nephrotoxicity is regarded as being
reversible and seems to be caused by a reduction in renal
blood ﬂow related to afferent arteriolar vasoconstriction.
However, the long-term administration of CsA causesThis work was supported by the National Natural Science
Foundation of China (No. 81160092) and a grant of the Korea
Healthcare technology R&D Project, Ministry for Health, Welfare
& Family Affairs of Korea (A092258).
Address reprint requests to Can Li, MD, PhD, Nephrology &
Dialysis Unit, Department of Internal Medicine, YanBian Univer-
sity Hospital, YanJi, JiLin, PR China, or Chul Woo Yang, MD,
PhD, Transplant Research Center, Seoul, St Mary’s Hospital,
College of Medicine, The Catholic University of Korea, Seoul
Korea. E-mail: canlimd@yahoo.com or yangch@catholic.ac.kr
0041-1345/13
http://dx.doi.org/10.1016/j.transproceed.2013.08.041
3127
Open access under CC BY-NC-ND license.
3128 XIANG, PIAO, ZOU ET ALprogressive renal insufﬁciency with striped tubulointerstitial
ﬁbrosis (TIF), tubular atrophy, inﬂammatory cell inﬂux, and
hyalinosis of the afferent arterioles.1,2 The mechanism
underlying chronic CsA nephropathy is multifactorial, and
several factors, including the intrarenal reninangiotensin
system, inﬂammatory mediators, the transforming growth
factor-beta 1 (TGF-b1), oxidative stress, apoptotic cell
death, and excessive autophagy, have been implicated in this
condition.2e5
Posttransplant diabetes mellitus (PTDM) is a common
and serious complication after kidney transplantation that
is associated with decreased graft and patient survival.6
A recent meta-analysis of observational studies and
randomized controlled trials reported that the incidence
of PTDM in the ﬁrst year after transplantation varied
from 2% to 50%. The incidence of PTDM is higher in the
ﬁrst 6 months after transplantation.7 Although its etio-
pathogenesis is multifactorial, PTDM is thought to be
related to the increased insulin resistance that results
from glucocorticoids8 and to the decreased insulin secre-
tion caused by calcineurin inhibitors.9,10 PTDM results in
adverse outcomes, such as decreased graft survival,
increased cardiovascular mortality, and increased risk of
postoperative infections.11
L-carnitine (b-hydroxy-g-N-trimethyl ammonium-butyrate)
is a component of lipid metabolism that is important for the
production of adenosine triphospate (ATP) through the b-
oxidation of long-chain fatty acids. In this manner, L-carnitine
functions as an indirect antioxidant and facilitates the repair
of oxidized membranes or lipid bilayers.12 In addition, L-
carnitine activity has also been reported to be a direct scav-
enger of O 2 and H2O2.
13 Thus, L-carnitine may possess
antioxidant properties beyond its action on lipid metabolism.
It is well known that L-carnitine is necessary for the efﬂux
of acyl groups from mitochondrial. Therefore, L-carnitine
supplementation is known to play a beneﬁcial role in in-
sulin resistance or diabetic podocyte injury,14,15 as intra-
cellular accumulation of acyl-CoA derivatives has been
implicated in the development of insulin resistance. Re-
cently, the renoprotective effects of L-carnitine have also
been reported in ischemia-reperfusion injury,16 cisplatin-
induced nephrotoxicit,17 doxorubicin-induced nephritic
syndrome,18 and chronic CsA nephropathy.19 Nevertheless,
the molecular mechanism underlying the beneﬁts of L-
carnitine on CsA-induced pancreatic and renal injuries
remains unexplored.
In view of the ﬁndings described above, the present study
was undertaken to evaluate the protective effect of L-
carnitine on CsA-induced pancreatic and renal injuries using
a well-described rat model of chronic CsA nephropathy.MATERIALS AND METHODS
Experimental design
The experimental protocol was approved by the Animal Care
Committee of the Catholic University of Korea. Male Sprague-
Dawley rats (Charles River Technology, Korea), initially weighing180 to 200 g, were housed in cages (Nalge Co, Rochester, NY,
USA) in a controlled-temperature and controlled-light environment
and allowed free access to a low salt diet (0.05% sodium, Teklad
Premier, Madison, Wis, USA) throughout the experimental period.
A total of 45 rats were randomized into 6 subgroups and treated
daily for 4 weeks as follows: (1) vehicle group (VH, n ¼ 7): rats
received olive oil (1 mL/kg/d subcutaneous) (2) VH þ L-carnitine
group (VH þ L50, n ¼ 7): rats received olive oil and L-carnitine
(50 mg/kg intravenously); (3) VH þ L-carnitine group (VH þ 200,
n ¼ 7): rats received olive oil and L-carnitine (200 mg/kg intrave-
nously); (4) CsA group (C, n ¼ 8): rats received CsA (15 mg/kg/
d subcutaneously); (5) CsA þ L-carnitine group (C þ L50, n ¼ 8):
rats received CsA and L-carnitine (50 mg/kg intravenously); (6)
CsA þ L-carnitine group (C þ L200, n ¼ 8): rats received CsA and
L-carnitine (200 mg/kg intravenously). The dosage and method of
CsA2 and L-carnitine administration20,21 were chosen based on
previous reports.
Animals were euthanized under ketamine anesthesia, and blood
and the kidney samples were collected for biochemical and
morphologic or molecular examinations.Basic Parameters
Rats were pair-fed and daily body weight (BW) was monitored.
Before sacriﬁce, rats were individually housed in metabolic cages
(Tecniplast Gazzada S. a r.l., Italy) for 24 hour-urine collection, and
blood samples were withdrawn to evaluate serum creatinine (SCr),
blood urea nitrogen (BUN), blood glucose levels, and plasma
insulin level (Coulter-STKS; Coulter Electronics). An intraperito-
neal glucose tolerance test (IPGTT) was performed at the end of
the 4-week treatment period as previously described,22 and the area
under the curve of glucose (AUCg) was calculated by trapezoidal
estimation from the values obtained in the IPGTT. Whole blood
CsA level was measured by a monoclonal radioimmunoassay
(Incstar Co, Stillwater, Minn, USA).Histopathology
Harvested rat kidney tissues were ﬁxed in periodate-lysine-
paraformaldehyde solution and embedded in wax. After dewaxing,
4 mm sections were processed and stained with Masson trichrome
and hematoxylin. A ﬁnding of TIF was deﬁned as a matrix-rich
expansion of the interstitium with tubular dilatation, tubular
atrophy, tubular cast formation, sloughing of tubular epithelial cells,
or thickening of the tubular basement membrane. A minimum of 20
ﬁelds per section was assessed using a color image analyzer (TDI
Scope Eye Version 3.0 for Windows, Olympus, Japan). Brieﬂy, the
images were captured, and the extent of TIF was quantiﬁed using
the Polygon program by counting the percentage of areas injured
per ﬁeld of cortex under 100 magniﬁcation. Histopathologic
analysis was performed in randomly selected cortical ﬁelds of
sections by a pathologist blinded to the identity of the treatment
groups.Enzyme-Linked Immunosorbent assay
Twenty-four-hour urinary concentrations of the DNA adduct 8-
hydroxy-20-deoxyguanosine (8-OHdG) were determined using
a competitive enzyme-linked immunesorbent assay (Japan Institute
for the Control of Aging, Shizuoka, Japan), according to the
manufacturer’s protocol. All samples were assayed in triplicate.
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After dewaxing, sections were incubated with a 0.5% Triton X100-
phosphate-buffered saline (PBS) solution for 30 minutes and
washed with PBS three times. Nonspeciﬁc binding sites were
blocked for 1 hour with normal donkey serum diluted 1:10 in PBS,
and then incubated overnight at 4C with anti-8-OHdG monoclonal
antibody (JaICA; Shizuoka, Japan) diluted in 1:1000 in a humid
environment. After rinsing in Tris-buffered saline (TBS), sections
were incubated in peroxidase-conjugated donkey anti-mouse or
rabbit IgG Fab fragment (Jackson Immuno Research Laboratories,
West Grove, Pa, USA) for 30 minutes. For staining, sections were
incubated with a mixture of 0.05% 3,3-diaminobenzidine containing
0.01% H2O2 at room temperature until a brown color was visible,
washed with TBS, counterstained with hematoxylin, and examined
under light microscopy. The procedure of immunostaining for TGF-
b1 (1:500, Santa Cruz Biotechnology, Inc) and ED-1 (1:500, Serotec
Inc, UK) was similar to that for 8-OHdG. Semiquantitative analyses
of TGF-b1 and ED-1 expression was performed using a color image
autoanalyzer (TDI Scope Eye Version 3.5 for Windows; Olympus,
Japan) by counting the percentage of stained areas per ﬁeld of
cortex at 100 magniﬁcation. A minimum of 20 ﬁelds per section
were counted and averaged.
Western Botting
Kidney cortex tissue was homogenized in lysis buffer (20 mmol/L
Tris-Cl [pH 7.6], 150 mmol/L NaCl, 1% [wt/vol] sodium deoxy-
cholate, 1% [vol/vol] Triton X-100, 0.1% sodium dodecyl sulfate,
2 mmol/L NaVO3, and freshly added 1% [vol/vol] aprotinin, leu-
peptin [l mg/mL], pepstatin [l mg/mL], and 1 mmol/L phenylmethyl
sulfonyl-ﬂuoride. Homogenates were centrifuged at 3000 rpm for
15 minutes at 4C, and the protein concentration of the lysate
was determined using a protein microassay of the Bradford method
(Bio-RAD, Hercules, California, USA). Protein samples were
resolved on 15% SDS-polyacrylamide gel electrophoresis and then
electroblotted onto Bio-Blot nitrocellulose membrane (Bio-RAD).
An equal amount of protein loading (80 mg) was veriﬁed by Ponceau
S staining. The membrane was blocked for 1 hour in TBS added
Tween-20 (TBS-T, 10 mmol/Tri-CL, 150 mmol/L NaCl [pH 8.0],
0.05% Tween-20) containing 5% nonfat powdered milk. Anti-
caspase-3, active form (1:200; Millipore Corporation, Calif, USA)
or microtubule-associated protein 1 light chain 3 phospholipid-
conjugated form (LC3- II, 1:1000; Sigma-Aldrich, USA) was
detected by incubating for 1 hour with speciﬁc primary antibodies.
Primary antibody incubation was followed by 6 washes of TBS-T.
The blot was then incubated with secondary antibody (Donkey
anti-rat IgG, horseradish peroxidase) conjugate at 1:2000 (Amer-
sham Biosciences, UK) for 1 hour. Antibody-reactive protein wasTable 1. Basic
VH VF þ L50 VH þ L200
WG 89.9  2.4 88.1  1.7 90.1  3.0
UV 11.6  1.3 16.0  1.7 13.7  1.9
SCr 0.42  0.03 0.35  0.03 0.34  0.02
BUN 11.3  0.48 10.7  0.90 11.0  0.63
CsA con 0  0 0  0 0  0
TIF 0  0 0  0 0  0
WG, weight gain (g); UV, urine volume (mL/d); SCr, serum creatinine (mg/dL); BUN
lointerstitial ﬁbrosis (%0.5/mm2) CsA, Cyclosporine; VH, vehicle group; L, L-carnitine
aP < .05 vs VH.
bP < .05 vs CsA.
cP < .05 vs CsA þ L50.detected using enhanced chemiluminescence (Amersham Biosci-
ences, UK). Optical densities were obtained using the VH group as
100% reference and normalized with b-actin.
Statistical Analysis
Data are expressed as mean  standard error of the mean unless
otherwise speciﬁed. Multiple comparisons among groups were
performed by one-way analysis of variance with the post hoc Bon-
ferroni test (SPSS software version 19.0, Microsoft Corp, Chicago,
Ill, USA). Statistical signiﬁcance was assumed as P < .05.
RESULTS
Effect of L-Carnitine on Basic Parameters in Chronic CsA
Nephropathy
CsA-treated rats exhibited weight loss (weight gain: 75.6 
2.6 vs 89.9  2.4, P < .01) and decreased renal function
(SCr, 0.55  0.02 mg/dL vs 0.42  0.03 mg/dL, P < .01;
BUN, 29.4  0.94 mg/dL vs 11.3  0.48 mg/dL, P < .01)
compared with VH-treated rats. However, BW was
increased (weight gain: 85.3  3.0 vs CsA, P < .05) and
renal function was improved after L-carnitine coadminis-
tration compared with the CsA group (SCr, 0.48  0.02 mg/
dL vs CsA, P < .05; BUN, 27.4  1.02 mg/dL vs CsA, P <
.05). Whole blood CsA concentration was unaffected by the
combination of L-carnitine and CsA, as shown in Table 1.
Effect of L-Carnitine on CsA-Induced Diabetes
Baseline blood glucose concentration did not differ between
the 6 groups (Fig 1A). IPGTT was signiﬁcantly increased in
the CsA group compared with the VH group, whereas the
CsA þ L group showed a signiﬁcant decrease in IPGTT
compared with the CsA group (Fig 1A). The calculated
AUCg did not differ signiﬁcantly between the VH and
VH þ L groups and was lower in the CsA þ L group than it
was in the CsA group (L50: 476.2  14.6 mg/dL minutes vs
44  11.2 mg/dL minutes, P < .05; L200: 476.2  14.6 mg/
dL minutes vs 396  9.6 mg/dL minutes, P < .05; Fig 1B).
Serum insulin level did not differ signiﬁcantly between the
VH and VH þ L groups. However, serum insulin concen-
tration in the CsA group was signiﬁcantly lower than that
observed in the VH (5.1  0.8 mg/dL minutes vs and 1.1 
0.3 mg/dL minutes, P < .05) and VH þ L group (L50: 5.1 
1.0 mg/dL minutes vs CsA, P < .05; L200: 4.8  0.4 mg/dL
minutes vs CsA, P < .05), and was signiﬁcantly higher in theParameters
CsA CsA þ L50 CsA þ L200
75.6  2.6a 85.4  3.5b 85.3  3.0b
18.6  2.7a 13.4  2.0 17.3  4.0
0.55  0.02a 0.48  0.02b 0.41  0.03c
29.4  0.94a 27.4  1.02b 23.8  1.32b
2207  205 2345  161 2409  225
34.1  3.2a 30.2  3.6b 28.7  2.5c
, blood urea nitrogen (mg/dL); CsA con, CsA concentration (ng/mL); TIF, tubu-
.
Fig 1. Effect of L-carnitine (L) on diabetic biomarkers. (A) Blood glucose levels (intraperitoneal glucose tolerance test [IPGTT]). (B)
Calculation of area under the curve of glucose (AUCg). (C) Plasma insulin levels. Note that cyclosporine (CsA) induced an elevation
in blood glucose and HbA1c and a decrease in plasma insulin levels, whereas coadministration of L reversed all of these parameters.
#P < .01 vs vehicle group of (VH); ##P < .05 vs CsA.
3130 XIANG, PIAO, ZOU ET ALCsA þ L group compared with the CsA group (L50: 2.7 
0.5 mg/dL minutes vs CsA, P < .05; L200: 2.8  0.2 mg/dL
minutes vs CsA, respectively; Fig 1C).Effect of L-Carnitine on Macrophage Inﬁltration and Fibrosis
in Chronic CsA Nephropathy
ED-1-positive cells were detected only rarely in the kidneys
of VH-treated animals. CsA treatment increased the
number of ED-1-positive cells (29  1.0/0.5 mm2 vs 5  0.7/
0.5 mm2, P < .01). Concomitant administration of L-carni-
tine signiﬁcantly decreased the number of ED-1-positive
cells (23  1.2/0.5 mm2 vs CsA, P < .01), which was more
pronounced after the administration of 200 mg/kg L-carni-
tine compared with the CsA þ L50 group (Fig 2, 19  2.0/
0.5 mm2 vs CsA þ L50, P < .05).
CsA-treated rats exhibited the typical striped TIF of
chronic CsA nephropathy (Table 1). A signiﬁcant increase
in the percentage of TIF was found in the CsA group
compared with the VH group (34.1%  3.2%/0.5 mm2 vs
0%  0%/0.5 mm2, P < .01). In contrast, the percentage of
TIF decreased markedly when L-carnitine was coadminis-
tered (28.7%  3.6%/0.5 mm2 vs CsA, P < .05) anda further decrease was observed in the CsA þ L200 group
(23.8  2.5%/0.5 mm2 vs CsA þ L50, P < .05).
Effect of L-Carnitine on TGF-b Expression in Chronic CsA
Nephropathy
Immunohistochemistry revealed that the majority of VH-
treated rat kidneys were negative for TGF-b1. In contrast,
the expression of the TGF-b1 protein was dramatically
increased in the tubulointerstitium in CsA-treated rat
kidneys (46.0%  2.3%/0.5 mm2 vs 17.1%  0.5%/0.5 mm2,
P < .01). It is notable that the sites of strong TGF-b1
protein expression were located in areas of inﬂammatory
cell inﬁltration and severe TIF (Fig 3A). L-carnitine sup-
pressed TGF-b1 protein expression in a dose-dependent
manner (CsA þ L50: 40.0%  1.4%/0.5 mm2, P < .05 vs
CsA; CsA þ L200: 30.2%  3.0%/0.5 mm2, P < .05 vs
CsA þ L50, respectively; Fig. 3B).
Effect of L-Carnitine on Oxidative Stress in Chronic CsA
Nephropathy
Chronic CsA nephropathy is closely associated with oxida-
tive stress. As shown in Fig 4, immunohistochemistry
showed a signiﬁcant increase in 8-OHdG expression and
Fig 2. Representative photomicrographs of immunohistochem-
istry (A) and semiquantitative analysis (B) of macrophage inﬁltra-
tion. Cyclosporine (CsA) treatment signiﬁcantly increased the
number of ED-1-positive cells, whereas this number was
decreased by cotreatment with L-carnitine (L). Immunohisto-
chemical staining: original magniﬁcation, 200. #P < .01 vs
vehicle group (VH); ##P < .05 vs CsA; *P < .05 vs CsA þ L50.
Fig 3. Representative photomicrographs of immunohistochem-
istry (A) and semiquantitative analysis (B) of transforming growth
factor (TGF)-b1 expression. Cyclosporine (CsA) signiﬁcantly
increased intrarenal TGF-b1 immunoreactivity, whereas this
was signiﬁcantly decreased by cotreatment with L-carnitine (L).
Immunohistochemical staining: original magniﬁcation, 200.
#P < 05 vs vehicle group (VH); #P < .05 vs CsA; *P < .05 vs
CsA þ L50.
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were conﬁned to cortical tubular epithelial cells. Interest-
ingly, the sites of strong 8-OHdG expression were located in
areas of injured or atrophied tubules (Fig 4A). Concomitant
administration of L-carnitine signiﬁcantly decreased intra-
renal 8-OHdG expression compared with the CsA treat-
ment alone. Moreover, this decrease was more pronounced
in the presence of a higher dose of L-carnitine compared
with the CsA þ L50 group. In parallel, urinary 8-OHdG
excretion in the CsA-treated group was higher than that
observed in the VH-treated group (241.0  37.2 ng/d vs
130.7  17.0 ng/d, P < .01), whereas its level wassigniﬁcantly decreased after concomitant administration of
L-carnitine, in a dose-dependent manner (Fig 4B, CsA þ
L50: 208.3 19.7 ng/d vs CsA, P < .05; CsA þ L200: 177.2 
12.7 ng/d vs CsA þ L50, P < .05, respectively).
Effect of L-Carnitine on LC3-II and Caspase-3 in Chronic
CsA Nephropathy
The presence of autophagy was measured based on LC3-II,
whereas apoptosis was assessed based on the detection of
the apoptosis-related caspase-3 protein, using Western
blotting. The results showed that CsA treatment upregu-
lated LC3-II (183%  11% vs 102%  6%, P < .01) and
Fig 4. Representative photomicrographs of immunohistochem-
istry (A) and enzyme-linked immunosorbent assay analysis of the
urinary output (B) of 8 hydroxy 20- deoxygulosine (8-OHdG) CsA
treatment signiﬁcantly increased intrarenal 8-OHdG immunoreac-
tivity and urinary 8-OHdG production, whereas these phenomena
were signiﬁcantly decreased by cotreatment with L-carnitine (L).
Immunohistochemical staining: original magniﬁcation, 200.
#P < .05 vs vehicle group (VH); ##P < .05 vs CsA; *P < .05 vs
CsA þ L50.
Fig 5. Western blotting of light chain 3 phospholipid conjugated
form (LC3-Il) and activated caspase-3. The increased expression
of LC3-II and caspase-3 observed in the cyclosporine (CsA)
group was signiﬁcantly suppressed after concomitant treatment
with L-carnitine (L). #P < .05 vs vehicle group (VH); ##P <.05 vs
CsA.
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with the VH group. Concomitant administration of L-
carnitine at a dose of 200 mg/kg inhibited the expression of
LC3-II (Fig 5A and Fig 5B, 133%  10% vs CsA, P < .05
and caspase-3 (Fig 5A and Fig 5C, 124%  12% vs CsA,
P < .05) expression.
DISCUSSION
The results of the present study demonstrate clearly that
L-carnitine offers a protective effect against CsA-inducedpancreatic and renal injuries in a rat model of chronic
CsA nephropathy. The renoprotective effect of L-carnitine
against CsA-induced renal injury was illustrated by its
inhibition of tubulointerstitial inﬂammation and ﬁbrosis,
apoptosis, and autophagy. In the pancreas, L-carnitine
treatment decreased CsA-induced diabetic control values.
Our ﬁndings may provide a potential rationale for the clin-
ical use of L-carnitine to reduce CsA-induced nephropathy
and diabetes.
The main pathogenesis of CsA-induced diabetes is caused
by the direct toxicity of CsA on pancreatic b cells, which
leads to a decrease in insulin secretion and synthesis23; in
contrast, insulin resistance plays a minor role in this
phenomenon.24 We demonstrated previously that CsA
treatment induces a dramatic reduction in pancreatic islet
size, insulin immunoreactivity, and vacuolization of islet
cells22 As a result, the present study measured blood dia-
betic controls. The results of this study revealed that CsA
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which was accompanied by a decrease in plasma insulin and
increase in hemoglobulin A1c (HbA1c). The concomitant
administration of L-carnitine reversed all of the biomarkers.
These ﬁndings suggest that L-carnitine may counteract CsA-
induced toxicity in the pancreas. Our results are consistent
with those reported by studies performed using human25
and animal20 samples, which revealed that L-carnitine
reverses blood glucose levels, insulin resistance, and HbA1c
levels.
The mechanism via which L-carnitine improved pancre-
atic function in this model is unknown; however, 2 possi-
bilities should be considered. First, chronic CsA treatment
induces oxidative stress injury, which ultimately leads to the
apoptosis of pancreatic b cells induced by low-density
lipoprotein.26 L-carnitine ameliorates pancreatic myeloper-
oxidase and glutathione-S-transferase enzymatic activities
in caerulin-induced acute pancreatitis via an antioxidant
effect.21 Second, mitochondrial dysfunction plays a central
role in ATP synthesis and content in b cells, which regulates
glucose-stimulated insulin secretion. Studies performed
in vivo27 and in vitro28 have conﬁrmed that L-carnitine
improves the mitochondrial membrane potential and upre-
gulates uncoupling protein-2, thus preventing mitochondrial
dysfunction in b cells.29 Based on our data regarding blood
glucose levels and previous reports, we propose that the
beneﬁts of L-carnitine on pancreatic b cells may be associ-
ated with its action on mitochondrial and oxidative stress.
The most notable ﬁnding of our study was that L-carni-
tine treatment suppressed inﬂammation and TIF in chronic
CsA nephropathy. As reported previously by our group2,30
and others,31 inﬂammation and TIF induced by CsA are
the typical pathologic features of chronic CsA nephropathy.
Moreover, the anti-inﬂammatory and antiﬁbrotic effects of
L-carnitine have been observed in isolated rat kidneys from
a rat model of this condition.32 However, the molecular
mechanism underlying the renoprotection afforded by L-
carnitine remains unknown. Therefore, this study assessed
the effect of L-carnitine on macrophage inﬂux and proﬁ-
brotic TGF-b1. We found that L-carnitine signiﬁcantly
decreased the number of ED-1-positive cells and TGF-b1
expression in a dose-dependent manner, which was ac-
companied by a marked attenuation of TIF. Our results
suggest that L-carnitine inhibits the development of tubu-
lointerstitial inﬂammation and ﬁbrosis in chronic CsA
nephropathy via a mechanism involving suppressed macro-
phage inﬂux and TGF-b1 expression.
It is well accepted that oxidative stress plays a pivotal role
in the pathogenesis of chronic CsA nephropathy. In addition,
overwhelming evidence suggests that CsA treatment induces
oxidative stress injury via the production of reactive oxygen
species and malondialdheyde and downregulation of antiox-
idant enzymes, such as superoxide dismutase and glutathione
peroxidase.33 This concept is supported by studies demon-
strating that antioxidant treatment signiﬁcantly ameliorates
chronic CsA-induced renal injury.34 L-carnitine, which is
a potential antioxidant agent, has been shown to protectagainst various types of nephrotoxicity in vivo17,35 and
in vitro36 via its antioxidant properties. In this study, we
found that L-carnitine decreased intrarenal 8-OHdG ex-
pression and urinary production. The suppression of oxida-
tive stress occurred in parallel with a signiﬁcant improvement
of renal function, as well as TIF. Our ﬁndings are supported
by the results of previous studies32,35 and suggest that the
renoprotective role of L-carnitine observed in this study may
be related, in part, to the inhibition of 8-OHdG.
L-carnitine protects against renal16 and myocardial37
ischemia-reperfusion injuries; in addition, its antiapoptotic
effect is regarded as a protective mechanism against ischemic
injury. More recently, we have shown that renal cell
apoptosis and excessive autophagy are closely associated with
the development of tubulointerstitial injury in chronic CsA
nephropathy.5 In the present study, we chose to compare 2
doses of L-carnitine (50 and 200 mg/kg). Interestingly, the
lower dose of L-carnitine did not inﬂuence apoptosis (active
caspase-3) and autophagy (LC3-II), whereas the higher dose
of L-carnitine improved not only pathologic damage, but also
apoptosis and autophagy. These observations suggest that,
although a low dose of L-carnitine (50 mk/kg) failed to
overcome the hemodynamic changes caused by CsA, this
compound was effective in preventing the development of
chronic CsA-induced nephropathy.
In summary, CsA-induced diabetes and renal injury
are common clinical dilemma in the transplantation ﬁeld.
Our results provide a rationale for the use of the non-
nephrotoxic agent L-carnitine in the management of dia-
betes in transplant recipients taking CsA.REFERENCES
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